CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Price & Overview
NASDAQ:CMMB • US16385C2035
Current stock price
The current stock price of CMMB is 1.61 USD. Today CMMB is down by -0.62%. In the past month the price increased by 3.87%. In the past year, price decreased by -69.27%.
CMMB Key Statistics
- Market Cap
- 11.593M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.76
- Dividend Yield
- N/A
CMMB Stock Performance
CMMB Stock Chart
CMMB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CMMB. When comparing the yearly performance of all stocks, CMMB is a bad performer in the overall market: 92.04% of all stocks are doing better.
CMMB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CMMB. While CMMB seems to be doing ok healthwise, there are quite some concerns on its profitability.
CMMB Earnings
CMMB Forecast & Estimates
8 analysts have analysed CMMB and the average price target is 15.3 USD. This implies a price increase of 850.31% is expected in the next year compared to the current price of 1.61.
CMMB Groups
Sector & Classification
CMMB Financial Highlights
Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -2.76. The EPS increased by 67.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.12% | ||
| ROE | -72.93% | ||
| Debt/Equity | 0 |
CMMB Ownership
CMMB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CMMB
Company Profile
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Company Info
IPO: 2012-08-14
CHEMOMAB THERAPEUTICS LTD
Kiryat Atidim, Building 7
TEL AVIV-YAFO 02139 IL
CEO: Neil Cohen
Employees: 20
Phone: 972773310156
CHEMOMAB THERAPEUTICS LTD / CMMB FAQ
Can you describe the business of CHEMOMAB THERAPEUTICS LTD?
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Can you provide the latest stock price for CHEMOMAB THERAPEUTICS LTD?
The current stock price of CMMB is 1.61 USD. The price decreased by -0.62% in the last trading session.
Does CHEMOMAB THERAPEUTICS LTD pay dividends?
CMMB does not pay a dividend.
What is the ChartMill rating of CHEMOMAB THERAPEUTICS LTD stock?
CMMB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy CMMB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CMMB.
Can you provide the upcoming earnings date for CHEMOMAB THERAPEUTICS LTD?
CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2026-05-13.